Annals of Surgical Oncology

, Volume 20, Issue 6, pp 1829–1836 | Cite as

Risk of Metachronous Colon Cancer Following Surgery for Rectal Cancer in Mismatch Repair Gene Mutation Carriers

  • Aung Ko Win
  • Susan ParryEmail author
  • Bryan Parry
  • Matthew F. Kalady
  • Finlay A. Macrae
  • Dennis J. Ahnen
  • Graeme P. Young
  • Lara Lipton
  • Ingrid Winship
  • Alex Boussioutas
  • Joanne P. Young
  • Daniel D. Buchanan
  • Julie Arnold
  • Loïc Le Marchand
  • Polly A. Newcomb
  • Robert W. Haile
  • Noralane M. Lindor
  • Steven Gallinger
  • John L. Hopper
  • Mark A. Jenkins
Colorectal Cancer



Despite regular surveillance colonoscopy, the metachronous colorectal cancer risk for mismatch repair (MMR) gene mutation carriers after segmental resection for colon cancer is high and total or subtotal colectomy is the preferred option. However, if the index cancer is in the rectum, management decisions are complicated by considerations of impaired bowel function. We aimed to estimate the risk of metachronous colon cancer for MMR gene mutation carriers who underwent a proctectomy for index rectal cancer.


This retrospective cohort study comprised 79 carriers of germline mutation in a MMR gene (18 MLH1, 55 MSH2, 4 MSH6, and 2 PMS2) from the Colon Cancer Family Registry who had had a proctectomy for index rectal cancer. Cumulative risks of metachronous colon cancer were calculated using the Kaplan–Meier method.


During median 9 years (range 1–32 years) of observation since the first diagnosis of rectal cancer, 21 carriers (27 %) were diagnosed with metachronous colon cancer (incidence 24.25, 95 % confidence interval [CI] 15.81–37.19 per 1,000 person-years). Cumulative risk of metachronous colon cancer was 19 % (95 % CI 9–31 %) at 10 years, 47 (95 % CI 31–68 %) at 20 years, and 69 % (95 % CI 45–89 %) at 30 years after surgical resection. The frequency of surveillance colonoscopy was 1 colonoscopy per 1.16 years (95 % CI 1.01–1.31 years). The AJCC stages of the metachronous cancers, where available, were 72 % stage I, 22 % stage II, and 6 % stage III.


Given the high metachronous colon cancer risk for MMR gene mutation carriers diagnosed with an index rectal cancer, proctocolectomy may need to be considered.


Rectal Cancer Lynch Syndrome Multiplex Ligation Dependent Probe Amplification Subtotal Colectomy Surveillance Colonoscopy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank all study participants of the Colon Cancer Family Registry and staff for their contributions to this project.


The authors have no conflict of interest to declare with respect to this manuscript.


This work was supported by the National Cancer Institute, National Institutes of Health under RFA #CA-95-011 and through cooperative agreements with members of the Colon Cancer Family Registry and Principal Investigators. Collaborating centers include Australasian Colorectal Cancer Family Registry (U01 CA097735), Familial Colorectal Neoplasia Collaborative Group (U01 CA074799) [USC], Mayo Clinic Cooperative Family Registry for Colon Cancer Studies (U01 CA074800), Ontario Registry for Studies of Familial Colorectal Cancer (U01 CA074783), Seattle Colorectal Cancer Family Registry (U01 CA074794), and University of Hawaii Colorectal Cancer Family Registry (U01 CA074806). AKW is supported by the Picchi Brothers Foundation Cancer Council Victoria Cancer Research Scholarship, Australia. MAJ is a Senior Research Fellow and JLH is an Australia Fellow of the National Health and Medical Research Council, Australia.

Supplementary material

10434_2012_2858_MOESM1_ESM.doc (72 kb)
Supplementary material 1 (DOC 73 kb)


  1. 1.
    Jenkins MA, Baglietto L, Dowty JG, Van Vliet CM, Smith L, Mead LJ, et al. Cancer risks for mismatch repair gene mutation carriers: a population-based early onset case-family study. Clin Gastroenterol Hepatol. 2006;4:489–98.PubMedCrossRefGoogle Scholar
  2. 2.
    Baglietto L, Lindor NM, Dowty JG, White DM, Wagner A, Gomez Garcia EB, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010;102:193–201.PubMedCrossRefGoogle Scholar
  3. 3.
    Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135:419–28.PubMedCrossRefGoogle Scholar
  4. 4.
    Bonadona V, Bonaiti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304–10.PubMedCrossRefGoogle Scholar
  5. 5.
    Vasen HFA, Abdirahman M, Brohet R, Langers AM, Kleibeuker JH, van Kouwen M, et al. One to 2-Year Surveillance Intervals Reduce Risk of Colorectal Cancer in Families With Lynch Syndrome. Gastroenterology. 2010;138:2300–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Parry S, Win AK, Parry B, Macrae FA, Gurrin LC, Church JM, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011;60:950–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Kalady MF. Surgical management of hereditary nonpolyposis colorectal cancer. Adv Surg. 2011;45:265–74.PubMedCrossRefGoogle Scholar
  8. 8.
    Kalady MF, Lipman J, McGannon E, Church JM. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. Ann Surg. 2012;255:1121–5.PubMedCrossRefGoogle Scholar
  9. 9.
    Coffey JC, Winter DC, Neary P, Murphy A, Redmond HP, Kirwan WO. Quality of life after ileal pouch-anal anastomosis: an evaluation of diet and other factors using the Cleveland Global Quality of Life instrument. Dis Colon Rectum. 2002;45:30–8.PubMedGoogle Scholar
  10. 10.
    Delaney CP, Fazio VW, Remzi FH, Hammel J, Church JM, Hull TL, et al. Prospective, age-related analysis of surgical results, functional outcome, and quality of life after ileal pouch-anal anastomosis. Ann Surg. 2003;238:221–8.PubMedGoogle Scholar
  11. 11.
    Fazio VW, Ziv Y, Church JM, Oakley JR, Lavery IC, Milsom JW, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Lee JS, Petrelli NJ, Rodriguez-Bigas MA. Rectal cancer in hereditary nonpolyposis colorectal cancer. Am J Surg. 2001;181:207–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Moslein G, Nelson H, Thibodeau S, Dozois RR. [Rectal carcinomas in HNPCC]. Langenbecks Arch Chir Suppl Kongressbd. 1998;115:1467–9.PubMedGoogle Scholar
  14. 14.
    Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2331–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol. 2005;23:6524–32.PubMedCrossRefGoogle Scholar
  16. 16.
    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.Google Scholar
  17. 17.
    Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, et al. Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012;30:958–64.PubMedCrossRefGoogle Scholar
  18. 18.
    Rogers WH. Regression standard errors in clustered samples. Stata Tech Bull. 1993;3:19–23.Google Scholar
  19. 19.
    Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics. 2000;56:645–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Stata Statistical Software: Release 11 [computer program]. College Station: StataCorp LP; 2009.Google Scholar
  21. 21.
    Young J, Simms LA, Biden KG, Wynter C, Whitehall V, Karamatic R, et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol. 2001;159:2107–16.PubMedCrossRefGoogle Scholar
  22. 22.
    Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32.PubMedCrossRefGoogle Scholar
  23. 23.
    Pohl H, Robertson DJ. Colorectal cancers detected after colonoscopy frequently result from missed lesions. Clin Gastroenterol Hepatol. 2010;8:858–64.PubMedCrossRefGoogle Scholar
  24. 24.
    Martinez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology. 2009;136:832–41.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Aung Ko Win
    • 1
  • Susan Parry
    • 2
    • 3
    Email author
  • Bryan Parry
    • 4
  • Matthew F. Kalady
    • 5
  • Finlay A. Macrae
    • 6
  • Dennis J. Ahnen
    • 7
  • Graeme P. Young
    • 8
  • Lara Lipton
    • 9
  • Ingrid Winship
    • 10
    • 11
  • Alex Boussioutas
    • 12
    • 13
    • 14
  • Joanne P. Young
    • 15
  • Daniel D. Buchanan
    • 15
  • Julie Arnold
    • 2
  • Loïc Le Marchand
    • 16
  • Polly A. Newcomb
    • 17
  • Robert W. Haile
    • 18
  • Noralane M. Lindor
    • 19
  • Steven Gallinger
    • 20
    • 21
  • John L. Hopper
    • 1
  • Mark A. Jenkins
    • 1
  1. 1.Centre for Molecular, Environmental, Genetic and Analytic EpidemiologyThe University of MelbourneParkvilleAustralia
  2. 2.New Zealand Familial Gastrointestinal Cancer RegistryAuckland City HospitalAucklandNew Zealand
  3. 3.Department of GastroenterologyMiddlemore HospitalAucklandNew Zealand
  4. 4.Colorectal Surgical UnitAuckland City HospitalAucklandNew Zealand
  5. 5.Department of Colorectal Surgery, Digestive Disease InstituteCleveland ClinicClevelandUSA
  6. 6.Colorectal Medicine and GeneticsThe Royal Melbourne HospitalParkvilleAustralia
  7. 7.Denver VA Medical Center, School of MedicineUniversity of ColoradoDenverUSA
  8. 8.Flinders Centre for Innovation in CancerFlinders UniversityAdelaideAustralia
  9. 9.Ludwig Institute for Cancer ResearchThe Royal Melbourne HospitalParkvilleAustralia
  10. 10.Department of MedicineThe University of MelbourneParkvilleAustralia
  11. 11.Genetic MedicineThe Royal Melbourne HospitalParkvilleAustralia
  12. 12.Department of MedicineRoyal Melbourne Hospital, The University of MelbourneParkvilleAustralia
  13. 13.Cancer Genomics and Predictive MedicinePeter MacCallum Cancer CentreEast MelbourneAustralia
  14. 14.Sir Peter MacCallum Department of OncologyThe University of MelbourneParkvilleAustralia
  15. 15.Cancer and Population Studies GroupQueensland Institute of Medical Research, Bancroft CentreHerstonAustralia
  16. 16.University of Hawaii Cancer CenterHonoluluUSA
  17. 17.Cancer Prevention ProgramFred Hutchinson Cancer Research CenterSeattleUSA
  18. 18.Department of Preventive MedicineUniversity of Southern CaliforniaLos AngelesUSA
  19. 19.Department of Health Science ResearchMayo Clinic ArizonaScottsdaleUSA
  20. 20.Samuel Lunenfeld Research InstituteMount Sinai HospitalTorontoCanada
  21. 21.Cancer Care OntarioTorontoCanada

Personalised recommendations